Pfizer Should Expand Maraviroc Postmarketing Safety Plans – Cmte.

Pfizer should conduct wide-ranging postmarketing studies to gather additional safety information on its CCR5 co-receptor antagonist maraviroc, FDA's Antiviral Drugs Advisory Committee recommended